As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Key Points Pfizer and Novo Nordisk have underperformed the market over the past year.But both should remain major players in ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Investing.com - UBS initiated coverage on 3SBio Inc (HK: 1530) (OTC:TRSBF) with a Buy rating and a price target of HK$30.00 on Friday. The pharmaceutical company, which focuses on haematology and ...

UBS views this record-making agreement as validation of 3SBio’s research and development capabilities, noting potential upside in SSGJ-707’s overseas peak sales and value from other pipeline ...

Meanwhile, RemeGen can acquire around 23% of Vor Bio's enlarged issued share capital through the $80 million in warrants, in place of a more standard cash payment, but this could be seen as a ...